Total submissions: 12
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000254683 | SCV000057383 | pathogenic | not provided | 2022-02-25 | criteria provided, single submitter | clinical testing | Reported previously in association with Noonan syndrome (Tartaglia et al., 2006; Musante et al., 2003); Published functional studies demonstrate a damaging effect; p.(E76D) results in abnormally increased activity levels of the PTPN11 protein (Tartaglia et al., 2006; Bocchinfuso et al., 2007); Missense variants in this gene are often considered pathogenic (HGMD); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 12634870, 20308328, 17177198, 29907801, 30029678, 16830086, 30050098, 32676024, 16358218, 24077912, 27535533, 11992261, 9491886, 16053901, 29493581) |
Laboratory for Molecular Medicine, |
RCV000037639 | SCV000061301 | pathogenic | Noonan syndrome | 2022-04-01 | criteria provided, single submitter | clinical testing | The p.Glu76Asp (c.228G>T) variant in PTPN11 has been reported in at least 10 individuals with clinical features of Noonan syndrome (Musante 2003 PMID: 12634870, Tartaglia 2006 PMID: 16358218, Power 2006 PMID: 16830086, Digilio 2011 PMID: 22190897, Zhu 2018 PMID: 30029678, Leach 2019 PMID: 29907801, LMM data) and has also been reported by other clinical laboratories in ClinVar (Variation ID 40502). It was absent from large population studies. Notably, a different nucleotide substitution at the same position (c.228G>C) resulting in the same amino acid change has been reported in >10 individuals with clinical features of Noonan syndrome (Tartaglia 2001 PMID: 11704759, Tartaglia 2006 PMID: 16358218, Edouard 2010 PMID: 20308328, LMM data). In addition, there are 4 other pathogenic amino acid substitutions at this position (p.Glu76Lys, p.Glu76Ala, p.Glu76Val, p.Glu76Gly); all these variants were also absent in large population studies. In vitro functional studies support an impact on protein function (Keilhack 2005 PMID: 15987685, Bocchinfuso 2007 PMID: 17177198, Edouard 2010 PMID: 20308328). Additionally, this variant lies in a location that has been defined by the ClinGen RASopathy Expert Panel to be a mutational hotspot or domain of PTPN11 (Gelb 2018 PMID: 29493581). In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant Noonan syndrome. ACMG/AMP Criteria applied: PS4, PM2_Supporting, PM5_Strong, PS3_Supporting. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000033478 | SCV000698072 | pathogenic | RASopathy | 2017-03-20 | criteria provided, single submitter | clinical testing | Variant summary: The PTPN11 c.228G>T (p.Glu76Asp) variant causes a missense change involving the alteration of a conserved nucleotide. 3/4 in silico tools predict a damaging outcome for this variant (SNPs&GO not captured due to low reliability index). This variant is absent in 122184 control chromosomes (ACMG PM2). This variant is found in the N-SH2 domain (IPR000980), a regulatory module of intracellular signaling cascades through its interaction with high affinity to phosphotyrosine-containing target peptides (ACMG PM1). This is a hotspot, with multiple missense variants in the same residue being known likely pathogenic variants (p.Glu76Lys, p.Glu76Ala, p.Glu76Val, p.Glu76Gly). In addition, multiple functional studies (Tartaglia_AJHG_2006, Edouard_MCB_2010, Keilhack_JBC_2005) showed that this variant increased basal and stimulated phosphatase activity by as much as 3-fold, determining a gain-of-function phenotype (ACMG PS3). This variant, and another variant c.228G>C that leads to the same amino acid change (E76D) have been reported in several patients with a clinical diagnosis of Noonan syndrome (ACMG PS1). In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as pathogenic (ACMG PP5). Lastly, these evidences support the classification of this variant as "Pathogenic" based upon ACMG guidelines (PS1, PS3, PM1, PM2, PP5). Taken together, this variant is classified as Pathogenic. |
Center of Genomic medicine, |
RCV000037639 | SCV000840427 | pathogenic | Noonan syndrome | 2018-04-13 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000762884 | SCV000893272 | pathogenic | Noonan syndrome 1; Juvenile myelomonocytic leukemia; Metachondromatosis; LEOPARD syndrome 1 | 2018-10-31 | criteria provided, single submitter | clinical testing | |
Blueprint Genetics | RCV000254683 | SCV000928217 | pathogenic | not provided | 2019-02-11 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000033478 | SCV001394745 | pathogenic | RASopathy | 2023-10-04 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamic acid, which is acidic and polar, with aspartic acid, which is acidic and polar, at codon 76 of the PTPN11 protein (p.Glu76Asp). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with Noonan syndrome (PMID: 11704759, 12634870, 16830086, 18678287, 22190897). ClinVar contains an entry for this variant (Variation ID: 40502). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on PTPN11 protein function. Experimental studies have shown that this missense change affects PTPN11 function (PMID: 15834506, 16358218, 17177198). For these reasons, this variant has been classified as Pathogenic. |
Genome Diagnostics Laboratory, |
RCV001813246 | SCV002060932 | pathogenic | Noonan syndrome and Noonan-related syndrome | 2020-08-05 | criteria provided, single submitter | clinical testing | |
Clinical Genetics Laboratory, |
RCV000254683 | SCV005197297 | pathogenic | not provided | 2022-07-13 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000033478 | SCV000196662 | pathogenic | RASopathy | no assertion criteria provided | clinical testing | Variant classified using ACMG guidelines | |
Division of Human Genetics, |
RCV003150934 | SCV003840156 | pathogenic | Noonan syndrome 1 | no assertion criteria provided | research | ||
Prevention |
RCV004734537 | SCV005362203 | pathogenic | PTPN11-related disorder | 2024-08-17 | no assertion criteria provided | clinical testing | The PTPN11 c.228G>T variant is predicted to result in the amino acid substitution p.Glu76Asp. This variant has been reported in many individuals with Noonan syndrome (Tartaglia et al. 2006. PubMed ID: 16358218; Table S3, Leach et al. 2019. PubMed ID: 29907801; Table S4, Zhu et al. 2018. PubMed ID: 30029678). Functional studies support this variants pathogenicity (Edouard et al. 2010. PubMed ID: 20308328). This variant has not been reported in a large population database, indicating this variant is rare. In ClinVar, this variant has been interpreted as pathogenic (https://www.ncbi.nlm.nih.gov/clinvar/variation/40502/). An alternate nucleotide substitution resulting in the same missense variant (c.228G>C (p.Glu76Asp)) has been reported as pathogenic (ClinVar ID: 40503). Alternate amino acid substitutions affecting this amino acid (p.Glu76Gln, p.Glu76Ala, p.Glu76Gly, p.Glu76Val) have been interpreted as pathogenic in ClinVar (ClinVar IDs: 181496, 13339, 13338, 13337). This variant is interpreted as pathogenic. |